

PROVINCIAL FUNDING SUMMARY

Vandetanib (Caprelsa) for Medullary Thyroid Cancer (pCODR 10090)

pERC Recommendation: Recommends

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: April 17, 2017

This information is current as of March 1, 2020.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Under provincial consideration		
AB	Funded	Sept 4, 2018	Vandetanib for the treatment of symptomatic and/or progressive medullary thyroid cancer in adult patients with unresectable locally advanced or metastatic disease, and with a good performance status
SK	Funded	Nov 15, 2018	Treatment of patients who have symptomatic and/or progressive medullary thyroid cancer (MTC) with unresectable, locally advanced or metastatic disease and with a good performance status. Treatment should continue until disease progression or unacceptable toxicity.
MB	Funded	Oct 18, 2018	For the treatment of patients who have symptomatic and/or progressive medullary thyroid cancer (MTC) with unresectable locally advanced or metastatic disease and with a good performance status. Treatment should continue until disease progression or unacceptable toxicity.
ON	Funded	Sept 13, 2018	For the treatment of symptomatic and/or progressive ¹ medullary thyroid cancer (MTC) in patients who meet the following criteria; (a) Patient has unresectable locally advanced or metastatic disease; AND (b) Vandetanib is being used as monotherapy for MTC; AND (c) ECOG less than or equal to 2; AND (d) Prescribed by or in consultation with an oncologist or internist experienced with the treatment of MTC.
NS	Funded	Dec 1, 2019	For the treatment of symptomatic and /or progressive medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Treatment should be for patients with a good performance status and

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
			should continue until disease progression or unacceptable toxicity.
NB	Funded	Dec 17, 2018	For the treatment of symptomatic and/or progressive medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Renewal Criteria: - Written confirmation that the patient has responded to treatment and there is no evidence of disease progression. Clinical Notes: 1. Patients must have a good performance status. 2. Treatment should be discontinued upon disease progression or unacceptable toxicity.
NL	Under provincial consideration		
PEI	Under provincial consideration		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.